‘With this individualized medicine we are able to identify subgroups of sufferers that can get better effects from certain drugs,’ he said. ‘In some instances there is a potential for a cure. Right now the cure rate for advanced lung tumor is 2-3 % at best. That is an enormous improvement but everything is based on the selection criteria.’ The CU College of Medication is a prominent innovator in lung cancer research. D. Ross Camidge, MD, Ph.D., scientific director of the Thoracic Oncology Plan at the University of Colorado Medical center and a Cancer Middle investigator, provides helped develop effective prescription drugs for sufferers with the ALK gene rearrangement, an abnormality that occurs in three to five % of lung tumor patients.Income from procedures was $0. Completely diluted earnings per share were $0.02 in comparison to for the initial nine months of 2013 and 2012 respectively, predicated on 11.20 million and 9.43 million shares outstanding. By September 30 Stability Sheet and CASHFLOW, 2013 we’d cash and money equivalents of around $10.55M and functioning capital of around $32.had and 84M a current ratio of 4:1. Our Accounts Receivable stability was approximately $13.on September 30 08M, 2013, versus approximately $21.85M at year end of 2012. The Organization's stockholders' collateral at of the finish the third one fourth of 2013 was $61.74M, with total property of $72.38M versus total liabilities of $10.64M.